Sonntag, 20. Juni 2021
Navigation öffnen
Anzeige:
Canakinumab
Canakinumab
 
JOURNAL ONKOLOGIE – STUDIE

A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

Rekrutierend

NCT-Nummer:
NCT04253015

Studienbeginn:
September 2019

Letztes Update:
29.03.2021

Wirkstoff:
-

Indikation (Clinical Trials):
Neuroblastoma

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
EusaPharma (UK) Limited

Collaborator:
United BioSource, LLC

Studienleiter

Jonathan Morgan, Dr
Study Director
EUSA Pharma (UK) Limited

Kontakt

Studienlocations
(3 von 14)

Charité Berlin
13353 Berlin
(Berlin)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Angelika Eggert, Dr
Phone: + 49 30 450 566 808
E-Mail: angelika.eggert@charite.de

Heidi Deubzer, Dr
Phone: + 49 30 450 566 808
E-Mail: heidi.deubzer@charite.de
» Ansprechpartner anzeigen
Interdisziplinäres Brustzentrum der Universitätsmedizin Greifswald
Ferdinand-Sauerbruch-Straße
17475 Greifswald Greifswald
(Mecklenburg-Vorpommern)
DeutschlandAktiv, nicht rekrutierend» Google-Maps
Lungenkrebszentrum Uniklinik Köln / Solingen
Kerpener Straße 62
50937 Köln
DeutschlandNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Thorsten Simon, Dr
Phone: +49 221-478-6850
E-Mail: thorsten.simon@uk-koeln.de

Pablo Landgraf, Dr
Phone: +49 221-478-6850
E-Mail: pablo.landgraf@uk-koeln.de
» Ansprechpartner anzeigen
Institut Gustave Roussy
94805 Villejuif
FranceNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Imene Hazem, Mr
Phone: 0033 1 42 11 50 20
E-Mail: Imene.HEZAM@gustaveroussy.fr

Fanny Prenois, Mrs
Phone: 0033 1 42 11 50 20
E-Mail: Fanny.PRENOIS@gustaveroussy.fr
» Ansprechpartner anzeigen
Uniwersytecki Szpital Dziecięcy
30-663 Kraków
PolandRekrutierend» Google-Maps
Ansprechpartner:
Aleksandra Wieczore, Dr
Phone: (+48) 12 3339392
E-Mail: a.wieczorek@uj.edu.pl

Walentyna Balwierz, Dr
Phone: (+48) 12 658 20 11
Phone (ext.): 4321
E-Mail: walentyna.balwierz@uj.edu.pl
» Ansprechpartner anzeigen
The Newcastle upon Tyne Hospitals NHS Foundation Trust
NE1 4LP Newcastle Upon Tyne
United KingdomNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Geoff Bell
Phone: 0191 282 1337
E-Mail: Geoff.Bell@nuth.nhs.uk

Linda Coates
Phone: 0191 2829964
E-Mail: Linda.Coates7@nhs.net
» Ansprechpartner anzeigen
Birmingham Children's Hospital
B4 6NH Birmingham
United KingdomAktiv, nicht rekrutierend» Google-Maps
University Hospital Southampton
SO16 6YD Southampton
United KingdomRekrutierend» Google-Maps
Ansprechpartner:
Ruth Lawrence
Phone: 02381206334
E-Mail: Ruth.Lawrence@uhs.nhs.uk

Alice Johnson
Phone: 02381206334
E-Mail: alice.johnson@uhs.nhs.uk
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

Rationale and Background:

Neuroblastoma, is the most common extra-cranial solid tumour in children. Most patients with

neuroblastoma are diagnosed under the age of 5 years and most present with metastatic disease

and/or high-risk features. Despite the introduction of novel treatment strategies, including

high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), the outcome

of these patients remains poor.

Dinutuximab beta is a chimeric monoclonal immunoglobulin G 1 (IgG1) antibody that is

specifically directed against the carbohydrate moiety of disialoganglioside antigen (GD2),

which is overexpressed on neuroblastoma cells. By binding to neuroblastoma cells, dinutuximab

beta can induce both complement dependent cytotoxicity (CDC) and antibody dependent

cell-mediated cytotoxicity (ADCC).

The efficacy of dinutuximab beta has been evaluated in a randomised controlled trial

comparing the administration of dinutuximab beta with or without interleukin 2 (IL-2) in the

first-line treatment of patients with high-risk neuroblastoma and in two singlearm studies in

the relapsed/refractory setting. The efficacy and safety of dinutuximab beta will further be

evaluated in this registry that will provide information on survival, pain severity and

incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular

events, hypersensitivity reactions and long-term safety.

Study Design:

This is a non-interventional, multi-national, observational, prospective patient registry of

patients with high-risk neuroblastoma being treated with the monoclonal antibody dinutuximab

beta. The efficacy and safety of dinutuximab beta will further be evaluated in this registry

that will provide information on survival, pain severity and incidence of neurotoxicity,

visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions

and long-term safety.

Research Questions and Objectives:

Primary objectives:

- To assess pain severity and use of analgesics during the period of first dose of

dinutuximab beta to end of last 35 day course of the 5th cycle of treatment

- To assess the incidence of neurotoxicity, visual impairment, capillary leak syndrome,

cardiovascular events and hypersensitivity reactions

- To assess the long term safety profile

Secondary objectives:

- Progression free survival (PFS) in patients treated with dinutuximab beta.

- Event Free Survival (EFS) in patients treated with dinutuximab beta

- Overall survival (OS) in patients treated with dinutuximab beta

Population:

Patients diagnosed with high-risk neuroblastoma who are starting treatment with dinutuximab

beta in the standard clinical practice setting or participating in a clinical trial where

dinutuximab beta is provided according to the indication as per the country/regional

marketing authorisation, provide consent/assent and are willing to be followed up for up to

10 years.

Study Size:

It is planned to enroll a sufficient number of patients (estimated at 125) such that 100

patients will have completed all five treatment courses of dinutuximab beta. It is

anticipated that this will result in 40-50 patients who are progression free at 10 years.

Data Sources:

Data will be collected from physicians using an electronic data capture (EDC) system. The

electronic case report forms (eCRFs) will be designed to gather data from the medical records

at baseline, during treatment and at normal clinical practice follow up visits.

Data Analysis:

The safety analysis set, containing all patients treated with at least one dose of

dinutuximab beta will be considered for safety and efficacy analyses. All baseline, treatment

period and follow up characteristics will be summarized using descriptive statistics.

Endpoints addressing primary and secondary analysis will include 95% confidence intervals

(CIs) including the Clopper Pearson method for binomial, log-log transform for survival. OS,

PFS and EFS will be analysed using Kaplan-Meier methods.

Variables:

Baseline (prior to start of treatment): Demographics, clinical trial participation,

neuroblastoma disease history, and presence or absence of neurotoxicity, visual impairment,

and cardiovascular abnormality.

Treatment period (up to end of last 35 day course of 5th cycle of treatment):

Dosing regimen, total cumulative amount of dinutuximab beta per course, concomitant

medications during course (IL-2, retinoic acid and/or antihistamines), daily analgesics

(opioids, gabapentin/ pregabalin and/or non-opioid analgesics and other neuropathic pain

treatments), daily pain assessment during infusion of dinutuximab beta, occurrence of

neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events, and

hypersensitivity reactions, adverse events (AEs)/serious adverse events (SAEs) treatment

interruptions and discontinuations, progression of disease, date and cause of death, reason

for study withdrawal (if applicable) Follow up (from end of last 35 day course of 5th cycle

of treatment): Status of neurotoxicity, visual impairment, cardiovascular events, (resolved,

not resolved), SAEs and adverse drug reaction (ADRs), progression of disease, date and cause

of death, reason for study withdrawal (if applicable).

Ein-/Ausschlusskriterien

Inclusion Criteria:

Patients meeting the following criteria will be considered for inclusion into the registry:

- Patients diagnosed with high-risk neuroblastoma and starting treatment with

commercially available dinutuximab beta OR

- Patients diagnosed with high-risk neuroblastoma and starting treatment with

dinutuximab beta in a clinical trial where dinutuximab beta is provided according to

the country/regional marketing authorisation AND

- Appropriate consent/assent has been obtained for participation in the registry with a

willingness to be followed up for up to 10 years.

Exclusion Criteria:

Patient will not be eligible for inclusion if the following criterion applies:

- Patients commencing dinutuximab beta within a clinical trial where the product is

being provided outside of the country/regional marketing authorisation OR

- Appropriate consent/assent has not been obtained for participation in the registry or

patient/legal representative is not willing for the patient be followed up for up to

10 years.

Studien-Rationale

Primary outcome:

1. Assessment of the severity of pain experienced by participants during treatment with dinutuximab beta (Time Frame - First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)):
Assessment of pain severity experienced by participants during the period of first dose of dinutuximab beta to the end of last 35 day course of 5th cycle of treatment

2. Number of participants using analgesics during treatment with dinutuximab beta (Time Frame - First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)):
Use of analgesics during the period of first dose of dinutuximab beta to end of last 35 day course of 5th cycle of treatment

3. Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions (Time Frame - First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)):
Incidence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions up to the end of the last 35 day course of 5th cycle of treatment

4. Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) during treatment with dinutuximab beta (Time Frame - First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)):
Number of participants experiencing serious adverse events (SAEs) and adverse drug reactions (ADRs) following the end of the last 35 day course of 5th cycle of treatment

Secondary outcome:

1. Overall Survival (OS) (Time Frame - First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)):
Overall Survival (OS) following the end of the last 35 day course of 5th cycle of treatment

2. Progression free survival (PFS) (Time Frame - First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)):
Progression free survival (PFS) following the end of the last 35 day course of 5th cycle of treatment

3. Event Free Survival (EFS) (Time Frame - First dose of dinutuximab beta to the end of the last 35 day course of the 5th cycle of treatment (each cycle is 35 days)):
Event Free Survival (EFS) following the end of the last 35 day course of 5th cycle of treatment

Geprüfte Regime

  • Data-collection:
    Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Kinder mit Leukämie – eine Herausforderung für die ganze Familie
Kinder+mit+Leuk%C3%A4mie+%E2%80%93+eine+Herausforderung+f%C3%BCr+die+ganze+Familie
© pingpao - stock.adobe.com

Wird bei einem Kind Leukämie diagnostiziert, so hat das für die ganze Familie dramatische Veränderungen zur Folge. Neben den gesundheitlichen Sorgen, tun sich weitere Problemfelder auf: Wie kann der Alltag organisiert werden trotz hoher physischer und emotionaler Belastung? Wie lassen sich Beruf, Betreuung des kranken Kindes in der Klinik und die Fürsorge für die Geschwister vereinbaren und welche finanziellen...

Hufeland-Preis ehrt Initiatoren eines bundesweiten Kita-Sonnenschutzprojekts zur Krebsprävention
Hufeland-Preis+ehrt+Initiatoren+eines+bundesweiten+Kita-Sonnenschutzprojekts+zur+Krebspr%C3%A4vention
© drubig-photo / Fotolia.com

Prof. Eckhard Breitbart, Vorsitzender der Arbeitsgemeinschaft für Dermatologische Prävention e.V. (ADP), Dr. Nadja Seidel und Dr. Friederike Stölzel, Leiterinnen des Präventionszentrums des Nationalen Centrums für Tumorerkrankungen Dresden (NCT/UCC) sind mit dem Hufeland-Preis des Kuratoriums der Stiftung Hufeland-Preis ausgezeichnet worden. Sie erhielten den mit 20.000 Euro dotierten Preis für...

Klinische Studien in der Krebstherapie – Informationen für Patienten
Klinische+Studien+in+der+Krebstherapie+%E2%80%93+Informationen+f%C3%BCr+Patienten
© Alexander Raths / Fotolia.com

Für Krebspatienten ist die Teilnahme an einer Studie mit der Chance verbunden, frühzeitig Zugang zu innovativen Behandlungsmethoden zu bekommen, die im klinischen Alltag nicht erhältlich sind. Neue Wirkstoffe bieten viele Chancen, können aber auch unbekannte Risiken und Nebenwirkungen mit sich bringen. Das ONKO-Internetportal erläutert, welche Arten von Studien es in der Krebstherapie gibt und was Patienten, die sich...

EHA 2021
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose
  • Hochrisiko-MDS und AML: Sabatolimab + Decitabin/Azacitidin zeigt in Phase-I-Studie anhaltende Remissionen bei guter Verträglichkeit
  • PNH: Neuer oraler Faktor-B-Inhibitor Iptacopan zeigt in Phase-II-Studie Wirksamkeit in der Erstlinie